CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $13.03M, lower than 95% of all stocks globally
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
39.16MILS13.03M · vs all stocks (USD)
Revenue (TTM)
1.18MUSD392.53K · vs all stocks (USD)
Beta
0.6200xvs all stocks
52-Week Change
-40.00%vs all stocks
Market Capitalization
39.16MILS13.03M · vs all stocks (USD)
Enterprise Value
39.23MILS13.05M · vs all stocks (USD)
Price to Sales (TTM)
27.93xvs Biotechnology peers
Price to Book (MRQ)
2.50xvs Biotechnology peers
Enterprise to Revenue
24.99xvs Biotechnology peers
Enterprise to EBITDA
-3.26xvs Biotechnology peers
Gross Margin
80.08%vs Biotechnology peers
Operating Margin
-629.77%vs Biotechnology peers
Return on Assets (TTM)
-16.55%vs Biotechnology peers
Return on Equity (TTM)
-46.72%vs Biotechnology peers
Revenue (TTM)
1.18MUSD392.53K · vs all stocks (USD)
Revenue per Share (TTM)
0.0010ILAUpdated Jul 26, 2026Quarterly Revenue Growth
87.10%vs Biotechnology peers
Gross Profit (TTM)
950.00KUSD316.02K · vs all stocks (USD)
Net Income (TTM)
-1.18MUSD-390.86K · vs all stocks (USD)
Operating Cash Flow (TTM)
2.34MUSD777.74K · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-1.18MUSD-390.86K · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00ILSUpdated Jul 26, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
5.15MUSDFY2025 · Dec 31, 2025Revenue
1.18MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
230.00KUSDFY2025 · Dec 31, 2025Gross Profit
950.00KUSDFY2025 · Dec 31, 2025Operating Income
-10.29MUSDvs all stocks (USD)
Pre-tax Income
-2.03MUSDFY2025 · Dec 31, 2025Net Income
-2.03MUSDFY2025 · Dec 31, 2025EBIT
-775.00KUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-9.19MUSDFY2025 · Dec 31, 2025Research & Development
8.09MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
3.92MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
1.12MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
1.25MUSDFY2025 · Dec 31, 2025EPS (Basic)
0.00USDFY2025 · Dec 31, 2025EPS (Diluted)
0.00USDFY2025 · Dec 31, 2025Basic Shares Outstanding
2.47BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
2.47BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-2.03MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
851.00KUSDFY2025 · Dec 31, 2025Operating Cash Flow
2.34MUSDFY2025 · Dec 31, 2025Free Cash Flow
2.31MUSDDerived from operating cash flow minus capital expenditure. This filing charges 523K of depreciation against 25K of capital expenditure, and its own free-cash-flow line reads -8.1M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
3.25MUSDFY2025 · Dec 31, 2025Interest Paid
1.27MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-2.03MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
523.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
396.00KUSDFY2025 · Dec 31, 2025Other Non-cash Items
18.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
2.43MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
997.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-25.00KUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-2.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-36.64MUSDFY2025 · Dec 31, 2025Sale of Investments
28.13MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-8.54MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
-5.01MUSDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-4.50MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
4.39MUSDFY2025 · Dec 31, 2025Shares Outstanding
2.61BSharesUpdated Jul 26, 2026Float Shares
2.50BSharesUpdated Jul 26, 2026% Held by Insiders
2.86%vs all stocks
% Held by Institutions
0.00%vs all stocks
Total Cash per Share (MRQ)
0.0070ILAUpdated Jul 26, 2026Total Debt (MRQ)
9.07MUSD3.02M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.4353xvs Biotechnology peers
Current Ratio (MRQ)
1.58xvs Biotechnology peers
Book Value per Share (MRQ)
0.0060ILAUpdated Jul 26, 2026Total Assets
40.91MUSDvs all stocks (USD)
Total Current Assets
23.68MUSDFY2025 · Dec 31, 2025Total Liabilities
17.56MUSDFY2025 · Dec 31, 2025Total Non-current Assets
17.22MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
5.44MUSDFY2025 · Dec 31, 2025Total Current Liabilities
12.12MUSDFY2025 · Dec 31, 2025Cash
632.00KUSDFY2025 · Dec 31, 2025Cash Equivalents
2.62MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
3.25MUSDFY2025 · Dec 31, 2025Other Short-term Investments
17.63MUSDFY2025 · Dec 31, 2025Accounts Receivable
46.00KUSDFY2025 · Dec 31, 2025Inventory
2.15MUSDFY2025 · Dec 31, 2025Accounts Payable
3.49MUSDFY2025 · Dec 31, 2025Short-term Debt
4.71MUSDFY2025 · Dec 31, 2025Other Current Liabilities
2.17MUSDFY2025 · Dec 31, 2025Long-term Debt
5.44MUSDFY2025 · Dec 31, 2025Common Stock (Book)
73.43MUSDFY2025 · Dec 31, 2025Retained Earnings
-401.00MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
23.34MUSDvs all stocks (USD)
52-Week Low
1.10ILAUpdated Jul 26, 202652-Week High
2.50ILAUpdated Jul 26, 202652-Week Change
-40.00%vs all stocks
Beta
0.6200xvs all stocks
50-Day MA
1.50ILAUpdated Jul 26, 2026200-Day MA
1.57ILAUpdated Jul 26, 2026Avg 10-Day Volume
1.51MSharesUpdated Jul 26, 2026Avg 30-Day Volume
2.87MSharesUpdated Jul 26, 2026Diluted EPS (TTM)
0.00ILAUpdated Jul 26, 2026Other Income / Expense
8.42MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $13.03M, lower than 95% of all stocks globallySignificant
Market cap (USD): 13,027,311.103Global P5: 269,387,740.27
Revenue is $392,527, lower than 95% of all stocks globallySignificant
Revenue (USD): 392,527Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Genflow Biosciences Plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Cizzle Biotechnology Holdings Plc
Tier 1ProductionApproval-Gated PipelineRule
Crism Therapeutics Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Cindrigo Holdings Limited
Tier 1ProductionApproval-Gated PipelineFlowRisk
Sailong Pharmaceutical Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Rua Life Sciences Plc
Tier 1ProductionApproval-Gated PipelineRule
Aptamer Group Plc
Tier 1ProductionApproval-Gated PipelineRule
Inspiration Healthcare Group plc
Tier 1ProductionApproval-Gated PipelineRule
Thalia Therapeutics Plc
Tier 1ProductionApproval-Gated PipelineRule
Sulzer Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow